The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV.

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they ...

GSK’s Arexvy and Pfizer’s Abrysvo are the top-selling RSV vaccines for older adults and will be joined in the next RSV season by Moderna’s recently approved mRESVIA. Meanwhile, Sanofi and AZ ...

As many as 20 people developed a potentially paralysing illness after getting the respiratory syncytial virus (RSV) vaccine.

The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only.

However, sales of the vaccine have been lukewarm, mainly due to the revised recommendations for RSV vaccinations issued by the Advisory Committee on Immunization Practices (“ACIP”) in June 2024.

The RSV vaccine, given between 32 and 36 weeks of pregnancy, helps expectant mothers pass protective antibodies to their babies—offering critical immunity in the earliest, most vulnerable months ...

The ongoing Phase I trial for Clover's combination vaccine candidates is enrolling up to 192 older adults (60-85 years), and the participants will be randomized to receive either SCB-1022 (RSV ...

Press Releases Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease ACCESS Newswire Updated June 12, 2025 7:42 PM ...

(RTTNews) - Moderna Inc. (MRNA) announced that the U.S. Food and Drug Administration has approved its respiratory syncytial virus (RSV) vaccine, mRESVIA (mRNA-1345), for preventing lower ...